216 results found | searching for "Pharmaceutical"

2 3 4 5 6 7 8 9 10 Next Last 
  • jameshebrew
  • AROUND 70% OF RNA EXTRACTION AND PURIFICATION KITS DEPLOY SPIN COLUMN TECHNOLOGY FOR EXTRACTION AND PURIFICATION OF RNA Amongst the total players involved in the development of RNA extraction and purification kits and reagents, majority of the players engaged in the development of RNA extraction and purification kits were established between 1981-2000. During our research, we were able to identify more than 60 developers were involved in the development of RNA extraction and purification kits and reagents. The RNA extraction and purification kits market is currently dominated by the presence of small companies. This is followed by the presence of well-established players in this domain. Further, most of the manufacturers of RNA extraction kits are headquartered in North America. Within this region, the US has emerged as the most prominent region, having the highest number of manufacturers. This is followed by the number of stakeholders headquartered in Asia-Pacific, with China and India being the base of operations for seven companies engaged in this domain. As can be observed in the figure, majority of the kits employ spin column technology for RNA extraction and purification. This is followed by the number of kits that employ magnetic beads technologies for the extraction and RNA purification. Further, maximum number of the kits have the ability to extract total RNA, followed by the kits that can extract viral RNA. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/rna-extraction-and-purification/request-sample.html It is evident from the figure that over 80% of the RNA isolated using RNA extraction and purification kits are used for PCR / RT-PCR applications, whereas 49% isolated RNA are used for blotting applications. It is worth mentioning that close to 50% kits are used to isolate RNA for SARS-CoV-2 analysis. With the increasing adoption of molecular diagnostics and introduction of novel and advanced RNA extraction and purification techniques, the RNA isolation and purification market is anticipated to witness steady growth in the coming years. For additional details, please visit https://www.rootsanalysis.com/reports/rna-extraction-and-purification.html You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • APTAMERS: THERAPEUTICS, TECHNOLOGIES, AND SERVICES MARKET – THE RISING REALM AMONGST STAKEHOLDERS IN PURSUIT OF ALTERNATIVE THERAPIES TO ANTIBODIES THERAPIES Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD). It has been reported that more than 15 million people in the US suffer from AMD alone with 200,000 cases annually across North America. This indicates a high unmet need of patients thus, paving a way for aptamer-based solutions due to their advantages over traditional antibody-based therapies. This has led to rapid developments in the domain which can be attributed to various factors, such as number in the number of clinical trials, increased awareness about advantages offered by aptamers as compared to antibodies, rise in the investment in the pharmaceutical research and development, along with rise in prevalence of chronic and rare diseases have contributed to the increase in the demand for aptamers-based therapeutics and diagnostic solutions. Aptamers are developed through the SELEX process and over the years these have become primary tools for aptamer synthesis. To ensure the development of more effective aptamer-based therapies candidates, several players have developed novel aptamer technologies that can be used for research, drug delivery and diagnostic applications. At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market/request-sample.html Over the past three decades, since the invention of SELEX by Larry Gold and Jack William in the 1990, the technology has seen several modifications to streamline and standardized aptamer-isolation process. These modifications substantially enhance efficiency / optimization to yield best possible aptamer or reduce the duration of the process. Other noteworthy developments in modifications of aptamers, include the addition of functional units of non-nucleic origin and nucleotide modifications, which further improves aptamer performance. Steps involved in the SELEX process:  Library Generation: Oligonucleotide library is created containing single-stranded nucleic acids having random sequences flanked by binding sites.  Binding and Separation: Target molecule is incubated along with the oligonucleotide library allowing for nucleic acids to bind to them resulting in the formation of aptamers. The remaining unbound nucleic acids are filtered out of the solution and through the process of elution the bound nucleic acid is separated from the target.  Amplification: The nucleic acids separated through the process of elution are then used to create a new library using the Polymerase Chain Reaction (PCR), this provides a new library that can be utilized for new round of SELEX thus, improving the quality of aptamers synthesized ADVANTAGES OF APTAMERS For many years, researchers have been raising and modifying antibodies to detect specific circulating proteins and develop targeted therapeutic agents. While antibodies are highly effective for a wide range of applications, there are unique aptamer advantages that can overcome some difficult scientific challenges.  Targets small molecules: Flexibility of aptamers offer wider applications as they can be developed against molecules as small as 60 Daltons this means aptamers can target molecules that are ten times smaller than antibody targets. Currently, aptamers for small molecule drugs, peptides, dyes and viral particles have been developed successfully.  Pursue toxic and non-immunogenic targets: Aptamer development process does not involve animals or living cells thus, making it possible to select aptamers for toxic compounds such as zootoxins and pathogenic bacteria. Additionally, aptamers do not require immune response and binding of tertiary aptamer structures to target molecules.  Penetrate tissues and cells: Due to their small size (30-80 nucleotides), they have enhanced ability to penetrate tissues thus, allowing them to reach specific targets efficiently. Some aptamers are able to enter cells without external assistance. For additional details, please visit:- https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market.html You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10% Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies. Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers. Key Market Insights Over 150 companies claim to offer companion diagnostics development services, globally Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers. Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers. Over 90 companies are actively involved in the development of companion diagnostics Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics. Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders. North America is expected to capture ~60% share in the companion diagnostics development services market by 2035 Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The ADC contract manufacturing market is projected to grow at a CAGR of more than 13% till 2035, claims Roots Analysis Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC developers. London Roots Analysis has announced the addition of “ADC Contract Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings. In order to mitigate the challenges associated with Antibody Drug Conjugate manufacturing, around 70-80% of the therapeutics developers prefer to outsource their operations to contract manufacturing organizations (CMOs), which claim to have the required expertise and experience to leverage their capabilities and yield cost savings opportunities. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/218/request-sample.html Key Market Insights Presently, more than 30 players claim to offer ADC contract manufacturing services This segment of the industry is dominated by the presence of large (more than 501 employees) and mid-sized (51-500 employees) players, which collectively represent more than 80% of the total contract manufacturers in this domain. In addition, around15% firms were established post 2010. More than 84 expansions were reported in this industry, during 2012-2021 Of the total, 57% instances were focused on enhancing dedicated capabilities and capacities, followed by those carried out for the expansion / establishment of manufacturing facilities (42%). Partnership activity in this domain has increased at a CAGR of over 16%, during 2016- 2021 Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (18%), followed by product development agreements (16%) and research agreements (15%). Further, most of the deals were inked by players based in Europe (46%). Global, installed ADC contract manufacturing capacity is currently estimated to be close to 33 Kilograms The maximum share of the current installed capacity is expected to be captured by large players. Moreover, close to 37% of the installed manufacturing capacity is available in the Asia-Pacific region. 140,200+ patients have been enrolled in over 714 clinical trials, worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 21%, in the past three years. Of the total number of trials, close to 47% of the studies are recruiting patients, while 30% have been completed. Global demand for ADC contract manufacturing is anticipated to grow at a CAGR of 13%, during 2022-2035 The commercial demand for ADC therapeutics is projected to increase at a CAGR of 22%. Further, the clinical demand for ADC therapeutics in phase III trials is projected to increase at a CAGR of 10%. The market is anticipated to grow at a CAGR of nearly 13%, during the period 2022-2035 In terms of type of cancer, ADC therapeutics targeting solid tumors (48%) are anticipated to capture the highest share; this trend is unlikely to change in the foreseen future. Further, based on type of antibody isotype, majority of the revenue share (90%) of the overall market is likely to be driven by IgG1 antibodies. While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information. For additional details please visit https://www.rootsanalysis.com/reports/view_document/adc-contract-manufacturing-market/218.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • Mubazgmi2
  • Citric Acid Market touched USD 3,070 million in 2020 and will grow at 3.5% CAGR during 2021-2028 | Size, Share, Analysis & Forecast The Citric Acid Market was valued around USD 3,070 million in 2020 and is expected to grow at a CAGR of 3.5% over the forecast period (2021-2028). The factors driving the growth of Citric Acid Market includes increasing application of citric acid in pharmaceutical and personal care industries, rising consumption of ice creams, low-calorie jellies and dietary beverages & snacks, consumers inclination towards the organic products and growing demand for ready-to-drink beverages and processed foods. For more info: https://www.openpr.com/news/2748928/citric-acid-market-touched-usd-3-070-million-in-2020-and-will-grow [more]
  • MubazGmi
  • Citric Acid Market reached USD 3,070 million in 2020 and will grow at 3.5% CAGR during 2021-2028 | Size, Share, Analysis & Report The Citric Acid Market was valued around USD 3,070 million in 2020 and is expected to grow at a CAGR of 3.5% over the forecast period (2021-2028). The factors driving the growth of Citric Acid Market includes increasing application of citric acid in pharmaceutical and personal care industries, rising consumption of ice creams, low-calorie jellies and dietary beverages & snacks, consumers inclination towards the organic products and growing demand for ready-to-drink beverages and processed foods. For more info: https://www.marketwatch.com/press-release/citric-acid-market-reached-usd-3070-million-in-2020-and-will-grow-at-35-cagr-during-2021-2028-size-share-analysis-report-2022-09-26 [more]
  • jameshebrew
  • PRESENTLY, MORE THAN 100 PLAYERS ACROSS THE GLOBE CLAIM TO OFFER NUTRIGENOMICS TESTS / SERVICES BASED ON GENETIC ASSESSMENT Given the recent shift from the one-size-fits-all model to a more personalized mode of treatment, there has been a growing interest in identification and adoption of novel techniques. It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advances in DNA sequencing technologies have enabled significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Further, the success of the Human Genome Project, which mapped the whole human DNA, has paved a path for the novel concept of nutrigenomics, the science studying the relationship between human genome, nutrition and health. One of the key objectives of the report was to evaluate the current opportunity and future potential associated with the nutrigenomics market, over the coming 13 years. We have provided informed estimates of the likely evolution of the nutrigenomics market in the short to mid-term and long term, for the period 2022-2035. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market/request-sample.html Presently, extensive studies are being conducted to understand the interaction between nutrients and gene expression at the molecular level to determine effect of a specific nutrient and dietary regime on the human health. Although the field of nutritional genomics is still in a nascent stage, it is a moving at a very fast-pace and is believed to have the potential to lay the foundation for personalized nutrition offerings. Further, the growing interest in nutrigenomics is supported by the rising awareness about the influence of diet on human health and its potential with respect to minimizing the risk of various diet-related diseases, including diabetes, cardiovascular disorders, chronic respiratory diseases and oncological disorders. It is worth mentioning that there are several companies that provide nutrigenomic test offerings directly to consumer, through availability of online genetic test kits and at-home sample collection facilities. Moreover, this field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. This field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. In this context, in the past 3 years, over 135 nutrigenomics focused research articles have been published, highlighting the active initiatives of researchers to illustrate the effect of nutrition on regulation of gene expression. At present, there are some ethical and regulatory challenges associated with nutrigenomics, including the potential misuse of personal data, as well as uncertainty related to genetic phenotypic predispositions, for conditions where no proven treatment exists. However, the benefits offered by nutrigenomics outweigh the uncertainty associated with its adoption. Considering the growing focus on personalized diets and active initiatives being undertaken by players in this domain, we are led to believe that the opportunity for stakeholders in this niche, but upcoming, industry is likely to grow at a commendable pace in the foreseen future. For additional details, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • RNAI THERAPY OFFERS THE POTENTIAL TO REVOLUTIONIZE THE BIOPHARMACEUTICAL INDUSTRY Owing to their vast potential in controlling disease-associated gene expression, RNAi therapeutics have emerged as a key segment of the market; several big pharma players have undertaken RNAi focused initiatives. In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics for in systemic delivery, paving the way for systemic applications of the therapy. A number of novel and sophisticated technologies / platforms have been / are being developed to overcome the challenges associated with RNAi therapeutics, as well as further enhance their specificity and stability. Further, considering their high knockdown efficiency, high target specificity and extended silencing ability, RNAi has now been established as a powerful tool for gene silencing. It is worth highlighting, RNAi has potential applications in treating several viral infections and tumors in addition to its ability in gene function determination. However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/278/request-sample.html With four approved drugs and several therapy candidates being evaluated in late stages of clinical development, the RNAi therapeutics domain presents a significant opportunity for biopharmaceutical developers. In addition, a number of RNAi therapeutics are being developed to target rare and genetic clinical conditions, such as Alpha 1-Antitrypsin Disease, Alport Syndrome, Amyloidosis and Muscular Dystrophy (Facioscapulohumeral Muscular Dystrophy and Oculopharyngeal Muscular Dystrophy). It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry. For additional details please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market/278.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The taste masking market is anticipated to grow at a steady pace till 2035, claims Roots Analysis Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years. London Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings. The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production. Key Market Insights Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%). Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions). Partnership activity in this field has grown significantly between 2018 and 2021 The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%). More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017 Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%). North America is anticipated to capture larger share of the market by 2035 The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:  Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)  David Tisi (Director of Technical Operations, Senopsys)  Brandon Keener (Business Development Associate, Adare Pharma Solutions) For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The DNA and gene cloning services market is anticipated to grow at a CAGR of over 15% by 2035, claims Roots Analysis In order to avail benefits, such as technical competence, reduced cost, and fast delivery of high-quality DNA and gene customized clones, several players have demonstrated a preference to leverage expertise of DNA and gene cloning service providers. London Roots Analysis has announced the addition of “DNA and Gene Cloning Market , 2022-2035” report to its list of offerings. DNA and gene cloning have diverse applications, including modern biotechnological, medicinal, and several diagnostic ones as DNA and gene cloning has proven to be beneficial for research and development in the biopharmaceutical and healthcare industries. Presently, a number of players having dedicated facilities, cutting-edge machinery, and production lines, are offering DNA and gene cloning services to the various stakeholders in this domain. In 1973, a group of scientists reported that individual genes can be cloned and isolated by cleaving DNA enzymatically into DNA fragments. Over time, gene and DNA cloning has proved to be an important tool for researchers in their studies focused on genetics Key Market Insights Around 80 companies claim to offer DNA and gene cloning services, globally Majority (59%) of the stakeholders are headquartered in North America, followed by those based in Europe (22%), and Asia-Pacific (19%). Further, this segment of the industry is dominated by the presence of small players (11-50 employees), representing 35% of the total service providers. Close to 32% players claim to act as one-stop-shops, offering services for gene synthesis, custom cloning, and sub-cloning Close to 80% of the DNA and gene cloning service providers offer custom cloning, followed by companies offering gene synthesis (68%), sub-cloning (50%), and other services, such as RNA cloning and vector cloning (31%). It is worth mentioning that most of the service providers (61%) offer restriction enzyme-based cloning. Close to 6,900 articles related to DNA and gene cloning, have been published in reputed scientific journals since 2018 More than 45% of the articles focused on DNA and gene cloning were published post-2019. Popular journals that have published multiple articles include Methods in Molecular Biology, International Journal of Biological Macromolecules, Developmental and Comparative Immunology, Protein Expression and Purification, and International Journal of Molecular Sciences. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/dna-and-gene-cloning-market/request-sample.html For additional details, please visit https://www.rootsanalysis.com/reports/dna-and-gene-cloning-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
2 3 4 5 6 7 8 9 10 Next Last